NRDN 101
Alternative Names: NDC 0009; NRDN-101Latest Information Update: 28 Jun 2025
At a glance
- Originator Neurodon
- Class Antihyperglycaemics; Small molecules
- Mechanism of Action Sarcoplasmic reticulum calcium-transporting ATPase stimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
- Available For Licensing Yes
Highest Development Phases
- Preclinical Type 2 diabetes mellitus
- No development reported Type 1 diabetes mellitus
Most Recent Events
- 28 Jun 2025 No recent reports of development identified for preclinical development in Type-1 diabetes mellitus in USA (PO)
- 21 Oct 2022 Pharmacodynamics data from preclinical study in Type 1 and Type 2 diabetes mellitus released by Neurodon (Neurodon pipeline, October 2022)
- 10 Nov 2021 Preclinical trials in Type 2 diabetes mellitus in USA (PO) (Neurodon pipeline, November 2021).